Trial Profile

Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (AFD): Impact of Treatment by Agalsidase Alpha (Replagal®)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Agalsidase alfa (Primary)
Indications Fabry's disease
Focus Diagnostic use
Acronyms MyFABT1

Most Recent Events

06 Feb 2026 Actual Primary Completion Date is 23 Jan 2023.
06 Feb 2026 Status changed from recruiting to completed.
25 May 2018 Planned End Date changed from 1 Dec 2020 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com